Acuitas Investments LLC Raises Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Acuitas Investments LLC increased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 38.6% in the 4th quarter, Holdings Channel reports. The firm owned 171,098 shares of the company’s stock after buying an additional 47,671 shares during the period. Acuitas Investments LLC’s holdings in Atea Pharmaceuticals were worth $522,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in AVIR. BML Capital Management LLC raised its stake in shares of Atea Pharmaceuticals by 13.8% during the fourth quarter. BML Capital Management LLC now owns 5,462,079 shares of the company’s stock worth $16,659,000 after purchasing an additional 662,079 shares during the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Atea Pharmaceuticals by 128.7% during the third quarter. Stonepine Capital Management LLC now owns 1,720,000 shares of the company’s stock worth $5,160,000 after buying an additional 967,912 shares in the last quarter. Sectoral Asset Management Inc. raised its holdings in Atea Pharmaceuticals by 19.7% in the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company’s stock valued at $1,801,000 after acquiring an additional 98,924 shares during the last quarter. Newtyn Management LLC grew its holdings in Atea Pharmaceuticals by 348.4% in the third quarter. Newtyn Management LLC now owns 400,000 shares of the company’s stock valued at $1,200,000 after purchasing an additional 310,803 shares during the period. Finally, GSA Capital Partners LLP grew its stake in shares of Atea Pharmaceuticals by 41.9% during the 3rd quarter. GSA Capital Partners LLP now owns 278,286 shares of the company’s stock valued at $835,000 after buying an additional 82,208 shares during the period. 86.67% of the stock is owned by institutional investors and hedge funds.

Atea Pharmaceuticals Stock Performance

Shares of AVIR traded down $0.01 during trading on Friday, reaching $3.68. The company’s stock had a trading volume of 34,626 shares, compared to its average volume of 418,215. Atea Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $5.19. The company has a fifty day moving average of $3.97 and a two-hundred day moving average of $3.52.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.03). Analysts forecast that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jean-Pierre Sommadossi sold 56,910 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $3.85, for a total transaction of $219,103.50. Following the sale, the chief executive officer now directly owns 116,557 shares in the company, valued at approximately $448,744.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Jean-Pierre Sommadossi sold 56,910 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.85, for a total value of $219,103.50. Following the completion of the sale, the chief executive officer now owns 116,557 shares in the company, valued at $448,744.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Wayne Foster sold 12,477 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $47,911.68. Following the completion of the sale, the chief accounting officer now owns 20,857 shares of the company’s stock, valued at $80,090.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,230 shares of company stock worth $327,852. Company insiders own 14.50% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.